Logotype for Dexcom Inc

Dexcom (DXCM) Q4 2019 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dexcom Inc

Q4 2019 earnings summary

4 Nov, 2026

Executive summary

  • 2019 revenue rose 43% to $1.476B, and net income reached $101.1M, marking the first full year of GAAP profitability.

  • Global active users reached an estimated 650,000 at year-end; G6 capacity doubled during 2019 as patient additions accelerated.

Financial highlights

  • FY19 revenue was $1,476.0M, up 43% YoY; gross profit was $931.5M, up 40%, and operating income was $142.3M versus a $186.3M operating loss in 2018.

  • FY19 net income was $101.1M versus a $127.1M net loss in 2018; diluted EPS was $1.10 versus a loss of $1.44.

  • Q4 revenue was $462.8M, gross profit $309.3M, operating expenses $207.8M, net income $92.7M, and diluted EPS $1.00.

  • Cash, cash equivalents and short-term marketable securities totaled $1,533.3M at year-end, up $147.7M YoY; operating cash flow was $314.5M.

  • Sensor and other revenue was 78% of FY19 total, versus 75% in 2018; reusable hardware contributed 22%, versus 25%.

Outlook and guidance

  • Capacity expansion is planned to continue in 2020 to support accelerating new-patient growth and sustain growth momentum.

  • Medicare G6 rollout continues; G6 launches are planned or expanding in selected international markets to broaden access.

  • Significant investment continues in next-generation disposable G7, whose smaller form factor is expected to improve user experience.

  • Longer-term opportunities include broader Type 2, prediabetes, pregnancy and hospital populations, alongside expanded global access and connected-device integration.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Dexcom